Skip to main content
. 2024 Mar 14;11:1295026. doi: 10.3389/fnut.2024.1295026

Table 2.

General parameters in the follow-up assessment.

Control SR SRPF Dunn’s adjusted value of p Dunn’s q value
Haemoglobin (g/dL) 14.33 [12.89; 15.42] 13.27 [12.08; 14.41]* 13.02 [11.93; 14.27]* 0.0692; 0.0253 0.0100; 0.0070
Glycate haemoglobin (mmol/mol) 5.57 [5.20; 5.80] 5.77 [5.19; 6.28] 6.24 [5.65; 8.12]*, 0.0003; 0.0338 0.0003; 0.0074
Lymphocytes (x1000/mm3) 1.89 [1.54; 2.35] 2.01 [1.56; 2.47]* 2.27 [1.78; 2.97]* 0.3877; 0.0035 0.0485; 0.0013
Platelets (×103/μL) 242.35 [197.78; 286.95] 259.10 [213.04; 303.55] 264.00 [219.35; 316.08] n.s. n.s.
CRP (mg/dL) 3.96 [1.40; 6.98] 5.77 [2.82; 10.45]* 6.08 [3.70; 10.33]* 0.0692; 0.0422 0.0100; 0.0074
D-dimer (mg/L) 410.02 [257.51; 580.05] 418.01 [228.75; 733.17] 463.00 [314.00; 720.00] n.s. n.s.

Comparisons were performed using the Kruskal-Wallis test followed by Dunn’s post-hoc test after adjustment by days to follow-up assessment. Statistical significance was considered when q < 0.052 in the Dunn’s post-hoc test. n.s. non-significant in Kruskall-Wallis test, post-hoc test not performed. * vs. Control; † vs. SR; CRP, C-reactive protein; SR, Self-Reported Symptoms group; SRPF, Self-Reported Symptoms and decreased Pulmonary Function group.